2016年-世界发展银行全球_Medicines_Regulatory_Systems_and_Scope_for_Regulatory_Harmonization_in_Southeast_Asia_79页_1mb

Summary of Medicines Regulatory Systems and Scope for Regulatory Harmonization in Southeast Asia

Core Content

This document provides an in-depth analysis of medicines regulatory systems and the potential for regulatory harmonization in Southeast Asia, with a focus on the Association of Southeast Asian Nations (ASEAN). It highlights the importance of medicines regulation in ensuring access to safe, effective, and affordable medicines, which is a critical component of achieving universal health coverage (UHC). The study examines the current state of pharmaceutical markets and regulatory frameworks in five ASEAN countries: Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.

Main Views and Key Information

1. Importance of Medicines Regulation

• Medicines regulation is essential to guarantee the availability of high-quality medicines.
• It involves multiple processes, including licensing, registration, inspection, quality control, and post-marketing surveillance.
• Effective regulation is vital to protect public health, as substandard or falsified medicines can lead to severe health consequences.

2. Challenges in Medicines Regulation

• National Medicines Regulatory Authorities (NMRAs) often lack sufficient technical expertise and institutional capacity.
• There is a backlog of applications and delays in the approval of new medicines, leading to a lag in market introduction.
• Limited resources and expertise hinder the ability of NMRAs to effectively monitor and regulate pharmaceutical products.

3. Pharmaceutical Market Trends in ASEAN

• ASEAN pharmaceutical markets are growing rapidly, but remain highly dependent on imported medicines, especially innovative ones.
• Local pharmaceutical production is increasing, with efforts to boost domestic manufacturing and reduce reliance on imports.
• Trade in pharmaceutical products is expanding, and harmonization can help reduce regulatory barriers and broaden export opportunities.

4. Regulatory Harmonization

• Regulatory harmonization aims to streamline and improve regulatory requirements by fostering a collaborative, cross-country approach.
• It is increasingly important due to the globalization of pharmaceutical production and the complexity of medicinal products.
• The ASEAN Pharmaceutical Product Working Group (PPWG) has been the main platform for harmonization efforts, including the adoption of the ASEAN Common Technical Document (ACTD) and a Mutual Recognition Agreement on GMP.

5. Barriers to Harmonization

• Differences in interpretation and implementation of guidelines among NMRAs.
• Limited institutional and technical capacity of NMRAs to carry out harmonization activities.
• Inadequate supervision and monitoring of work plans and progress.

6. Recommendations

• Improve institutional and technical capacity of NMRAs and the pharmaceutical industry.
• Strengthen the concept of referencing and reliance on data from stringent regulatory authorities.
• Provide operational support to regional platforms like PPWG to enhance implementation.
• Increase coordination among regulators and partners to avoid duplication and enhance support for harmonization.

Key Findings

• Access to Medicines: Despite global and national efforts, millions of people in low- and middle-income countries still lack access to quality-assured and affordable medicines.
• Health Expenditure: Medicines contribute to a significant share of total health expenditure, with variations across countries.
• Regulatory Capabilities: NMRAs in the region face constraints in both technical and institutional capacity.
• Harmonization Progress: ASEAN has made progress in regulatory harmonization, but implementation remains uneven.

Opportunities and Constraints

Opportunities

• Collaborative Efforts: Regional initiatives enable the pooling of resources and expertise.
• Economic Benefits: Harmonized standards can reduce the cost of review and improve market access for domestic manufacturers.
• Improved Access: Harmonization can help ensure timely access to quality and affordable medicines.

Constraints

• Technical and Institutional Limitations: Many NMRAs lack the necessary expertise and infrastructure.
• Workload and Backlog: High application volumes lead to delays in the approval process.
• Policy Tensions: National policies may prioritize domestic interests over regional harmonization.

Conclusion

The study concludes that regulatory harmonization in ASEAN is crucial for improving access to medicines and enhancing the efficiency of the pharmaceutical sector. It emphasizes the need for stronger collaboration, better capacity development, and increased coordination among stakeholders to achieve sustainable and effective regulatory systems.